Congress of the United States

Washington, DC 20515

November 14, 2023

The Honorable Xavier Becerra Secretary US Department of Health and Human Services 200 Independence Avenue, SW Washington, D.C. 20101 Robert M. Califf, MD Commissioner Food and Drug Administration 10903 New Hampshire Ave Silver Spring, MD 20993

Melanie Fontes Rainer Director Office for Civil Rights U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201

Dear Secretary Becerra, Commissioner Califf, and Director Fontes Rainer:

Thank you for your leadership and collaboration in spurring adequate supply and nondiscriminatory distribution of critical medications. The dual threats of short supply and unintended chilling effects of abortion restrictions and bans have in some circumstances made accessing certain medications for chronic conditions and reproductive health particularly difficult, if those medications can also be used for or cause an abortion. We are reaching out today because these factors continue to hinder access to the medications methotrexate and misoprostol.

Methotrexate is a commonly prescribed medication used to treat rheumatoid arthritis (RA), other autoimmune disorders, and some cancers, including breast cancer, lymphoma and leukemia, among other conditions. It is an antimetabolite which alleviates RA by reducing the activity of the immune system. It is Food and Drug Administration approved and often the first line of defense against RA, being used to treat inflammation which cannot be controlled by a biologic alone. Its injectable form is used to treat ectopic pregnancy. Misoprostol is a medication used to prevent gastric ulcers, for miscarriage management, and for abortion.

Since the Supreme Court's *Dobbs v. Jackson Women's Health Organization* decision in June 2022, people across the country have been denied access to methotrexate and misoprostol. In many states, physicians, other types of providers, and pharmacists must comply with extreme and often confusing abortion bans and restrictions. These laws have created a chilling effect in which providers are fearful to offer medications like methotrexate and misoprostol to manage chronic conditions or for miscarriage management, because they could under another use be used for or cause an abortion.¹ While we appreciate the statement on July 13, 2022, from

¹ https://www.reuters.com/world/us/state-abortion-bans-prevent-women-getting-essential-medication-2022-07-14/

the Department of Health and Human Services reminding retail pharmacies of their obligation to supply prescribed medications in a nondiscriminatory manner, this issue persists.²

Further, the supply chain for methotrexate is at risk, and manufacturers have not kept up with demand.³ In Spring 2023, Akorn Pharmaceuticals, the largest manufacturer of generic methotrexate filed for Chapter 7 bankruptcy and closed. This has left a gap in the market, which has contributed to the shortage of the medication.

Without access to this critical medication, people's lives are at risk. In response to this shortage, we request answers to the following:

- 1. What steps are HHS and the FDA taking to strengthen the supply chain for methotrexate, and ensure an adequate supply of this medication?
- 2. What barriers to the manufacture and distribution of methotrexate remain?
- 3. What Congressional support or assistance do HHS and the FDA need to address these barriers and ensure adequate supply and distribution of methotrexate?
- 4. In addition to monitoring and enforcement actions, what proactive steps is the Office for Civil Rights taking to ensure that all pharmacy retailers are dispensing reproductive health medications and medications for chronic conditions, like methotrexate and misoprostol, in a nondiscriminatory manner?

We request your prompt response to these questions and appreciate your collaboration in restoring access to care for people across the country.

Sincerely,

Caston

Member of Congress

Becca Balint

² https://www.hhs.gov/civil-rights/for-individuals/special-topics/reproductive-healthcare/pharmacies-guidance/index.html

³ https://www.the-rheumatologist.org/article/methotrexate-shortage-why-its-happening-potential-solutions/

Member of Congress

-N Tokude

Member of Congress

Nikki Budzinski Member of Congress

Member of Congress

Member of Congress

Paul Tonko

Member of Congress

Mike Quigley

Member of Congress

Seth Moulton

Member of Congress

Member of C

Eleanor Holmes Norton Member of Congress

Member of Congress

Jasmine Crockett Member of Congress

David J. Trone

Member of Congress

Nydia M. Velázquez Member of Congress

Andrea Salinas
Member of Congress

Kevin Mullin
Member of Congress

Raúl M. Grijalva Member of Congress

Katie Porter Member of Congress

Josh Gottheimer Member of Congress

Member of Congress

Bradley Scott Schneider Member of Congress

en forthe kneede

Jerrold Nadler

Member of Congress

Member of Congress

Member of Congress

Betty McCollum

Member of Congress

Morgan McGarvey
Member of Congress

Dan Goldman

Member of Congress

Ted W. Lien

Pramila Jayapal Member of Congress

Deborah K. Ross Member of Congress Brittany Pettersen Member of Congress

Steve Cohen

Member of Congress

Alma S. Adams, Ph.D. Member of Congress

Member of Congress

Gregory W. Meeks Member of Congress Jan Schakowsky
Member of Congress

Angie Craig

Member of Congress

Kathy Castor

Joseph D. Morelle Member of Congress

Manette Diaz Barragán
Member of Congress

Jaseph D. Marelle

Adam B. Schiff Member of Congress

Madeleine Dean
Member of Congress

Jonathan L. Jackson Member of Congress Mark Pocan
Member of Congress

Troy Carter

Member of Congress

Colin Z. Allred Member of Congress

Salud Carbajal Member of Congress

Ruben Gallego
Member of Congress

Haley M. Stevens Member of Congress

Dina Titus